In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.
86 citations
,
January 2020 in “British Journal of Dermatology” This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.
August 2025 in “American Journal of Clinical Dermatology” This vodcast discusses various tools for assessing the severity of alopecia areata, emphasizing the importance of considering psychosocial impacts alongside physical symptoms.
November 2024 in “SKIN The Journal of Cutaneous Medicine” In this study, NH Asian alopecia areata patients reported the highest levels of severe disease, with NH White patients having the most eyebrow involvement and Hispanic patients showing the least severity.
October 2024 in “La Tunisie Médicale” In this cross-sectional study conducted at Farhat Hached Hospital in Tunisia, more than half of the 60 alopecia areata patients surveyed experienced depression, particularly younger individuals and those with severe or specific forms of the condition, underscoring the need for psychological support.